Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod

Retrieved on: 2021-03-08 13:53:23

Tags for this article:

Click the tags to see associated articles and topics

Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod. View article details on hiswai:

Excerpt

Roche's Tecentriq, in withdrawing a bladder cancer indication, became the latest target in an FDA campaign reconsidering accelerated approvals ...

Article found on: www.fiercepharma.com